Lilly (LLY) Presents Data From Diabetes Studies At ADA Meet
Zacks Investment Research | Jun 10, 2019 08:40AM ET
Eli Lilly and Company (NYSE:LLY) presented additional data from two phase III studies — PRONTO-T1D and PRONTO-T2D — evaluating its investigational ultra-rapid-acting lispro (URLi) for the treatment of type I and type II diabetesat the scientific session of the American Diabetes Association (ADA).
In October last year, Lilly had announced that the studies met the primary efficacy endpoint. Data presented from the studies showed that URLi was non-inferior to Humalog in controlling A1C (an overall measure of glucose control) while significantly lowering post meal blood glucose levels in type I and type II diabetes patients.
Lilly confirmed these observations along with the latest release and also said that treatment with URLi led to superior reduction in blood glucose spikes at both one hour and two hours after a test meal compared to Humalog. The data also showed that URLi significantly improved glucose time in range during the day. The data thus indicates that URLi may help control blood glucose post meals, thereby addressing a concern for patients taking mealtime insulin who experience high blood glucose levels after eating
Lilly has submitted regulatory applications for URLi based on data from these studies in Europe and Japan. It plans to submit the same in the United States later this year.
Lilly’s shares have risen 2.2% this year so far compared with the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.